FDA Approves Tagrisso as First-Line Treatment for Lung Cancer

The FDA approved AstraZeneca’s Tagrisso as a first-line treatment for patients with metastatic non-small cell lung cancer with tumors experiencing epidermal growth factor receptor mutations.

The approval was based on successful results from the Phase III trial, in which the drug met the primary endpoint of progression-free survival.

The medication was previously approved as a second-line treatment for patients whose disease has progressed on or after a first-line therapy and who have developed the secondary T790M mutation.